Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections

-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform-San Diego, California, Aug 14, 2019 –Forge Therapeutics, Inc. (Forge), a biotechnology company developing [...]

2019-08-13T20:58:24-07:00August 14th, 2019|

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

  San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea [...]

2019-04-24T09:39:15-07:00April 24th, 2019|

Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference

-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. [...]

2019-03-11T11:07:30-07:00March 11th, 2019|

Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections

  San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that [...]

2019-01-03T10:51:05-08:00January 3rd, 2019|